Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Alzheimer's Disease Neuroimaging Initiative
100%
Alzheimer's Disease
77%
Alzheime's Disease
66%
Cerebrospinal Fluid Biomarkers
55%
Cardiac Magnetic Resonance Imaging (cMRI)
44%
Control Subjects
22%
Mild Cognitive Impairment
22%
Rate of Change
22%
Early Detection
22%
Risk Loci
22%
Clinical Test
22%
Neurodegeneration
11%
Brain Atrophy
11%
Disease Severity
11%
Clinical Data
11%
National Institutes of Health
11%
Pharmaceutical Companies
11%
Change Patterns
11%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
11%
Alzheimer's Disease Risk
11%
Alzheimer's Disease Pathology
11%
Competing Hypotheses
11%
Multimodality
11%
Early Alzheimer's Disease
11%
Provided Support
11%
Disease-modifying Therapy
11%
Normal Aging
11%
Preclinical Imaging
11%
Change of Measure
11%
National Institute on Aging
11%
Biochemical Biomarkers
11%
Pathobiology
11%
Imaging Biomarkers
11%
Australia
11%
Biomarker Testing
11%
Imaging Genetics
11%
Alzheimer
11%
Tau Positron Emission Tomography
11%
Diagnostic Methods
11%
Mildly Symptomatic
11%
Etiopathogenesis
11%
Process Data
11%
Disease Trajectory
11%
Clinical Decline
11%
Clinical Biomarkers
11%
Biomarker Data
11%
Standardized Method
11%
Embargo
11%
Amnestic Mild Cognitive Impairment (aMCI)
11%
Brain Hypometabolism
11%
Alzheimer Patients
11%
Alternative Assessment
11%
Amyloid Cascade
11%
PICALM
11%
Early Tracking
11%
Efficient Outcomes
11%
Positron Emission Tomography/computed Tomography (PET/CT)
11%
Amyloid Positron Emission Tomography
11%
Preclinical Stage
11%
Biomarker Assessment
11%
Genetic Biomarkers
11%
Europe-Asia
11%
Cognitive Impairment Diseases
11%
Clinical Trial Efficiency
11%
Optimum Features
11%
Biochemistry, Genetics and Molecular Biology
Magnetic Resonance Imaging
100%
Positron Emission Tomography
75%
Amyloid Protein
75%
Tau
50%
Clinical Trial
25%
Sample Size
25%
Imaging Genetics
25%
PICALM
25%
Neuroscience
Alzheimer's Disease
100%
Biological Marker
35%
Magnetic Resonance Imaging
20%
Positron Emission Tomography
15%
Mild Cognitive Impairment
15%
Amyloid Protein
15%
Neurodegeneration
5%
Fluorine-18
5%
Genetics
5%